

## 2026 CALENDAR OF FINANCIAL COMMUNICATION

**Vetoquinol published its calendar of financial communication for 2026.**

January 29, 2026	2025 Annual Sales (after market)
March 27, 2026	2025 Annual results (confcall before market)
April 28, 2026	2026 First quarter sales (after market)
May 20, 2026	Annual shareholders' meeting
June 8, 2026	Dividend payment
September 11, 2026	2026 First semester results (confcall before market)
October 28, 2026	2026 Third quarter sales (after market)

FOR MORE INFORMATION,  
CONTACT:

### VETOQUINOL

#### Investor Relations

**Josette Molle-Yukna**

Tel.: +33 (0)3 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**Next update:** Annual Sales 2025, January 29<sup>th</sup>, 2026 after market close

#### ABOUT VETOQUINOL

Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas, and Asia/Pacific.

Independent and a pure player, Vetoquinol innovates, develops, and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and companion animals (dogs, cats).

Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories have ensured hybrid growth for the Group. As of June 30, 2025, Vetoquinol employed 2,497 people.

Vetoquinol has been listed on Euronext Paris since 2006 (ticker symbol: VETO). The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.

